162 related articles for article (PubMed ID: 11822746)
1. Pre-operative endocrine therapy for postmenopausal women: when and why?
Tondini C; Fenaroli P; Labianca R
Ann Oncol; 2001 Nov; 12(11):1505-6. PubMed ID: 11822746
[No Abstract] [Full Text] [Related]
2. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
Eiermann W; Paepke S; Appfelstaedt J; Llombart-Cussac A; Eremin J; Vinholes J; Mauriac L; Ellis M; Lassus M; Chaudri-Ross HA; Dugan M; Borgs M;
Ann Oncol; 2001 Nov; 12(11):1527-32. PubMed ID: 11822750
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
4. Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
DeGrendele H
Clin Breast Cancer; 2003 Dec; 4(5):311-2. PubMed ID: 14715105
[No Abstract] [Full Text] [Related]
5. Letrozole after tamoxifen for breast cancer--what is the price of success?
Bryant J; Wolmark N
N Engl J Med; 2003 Nov; 349(19):1855-7. PubMed ID: 14551339
[No Abstract] [Full Text] [Related]
6. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
7. Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.
Burstein HJ
N Engl J Med; 2003 Nov; 349(19):1857-9. PubMed ID: 14551340
[No Abstract] [Full Text] [Related]
8. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Dixon JM; Love CD; Renshaw L; Bellamy C; Cameron DA; Miller WR; Leonard RC
Endocr Relat Cancer; 1999 Jun; 6(2):227-30. PubMed ID: 10731113
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer studies challenge tamoxifen therapy.
Timms B
Lancet Oncol; 2000 Nov; 1():132. PubMed ID: 11905647
[No Abstract] [Full Text] [Related]
10. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
Buzdar AU; Vergote I; Sainsbury R
Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Dixon JM; Jackson J; Renshaw L; Miller WR
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
[TBL] [Abstract][Full Text] [Related]
13. Letrozole in breast cancer.
Shahab N
N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
[No Abstract] [Full Text] [Related]
14. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Illiger HJ
Strahlenther Onkol; 2002 Feb; 178(2):111-3. PubMed ID: 11942036
[No Abstract] [Full Text] [Related]
15. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
16. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Tominaga T; Adachi I; Sasaki Y; Tabei T; Ikeda T; Takatsuka Y; Toi M; Suwa T; Ohashi Y
Ann Oncol; 2003 Jan; 14(1):62-70. PubMed ID: 12488294
[TBL] [Abstract][Full Text] [Related]
17. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors for breast cancer in postmenopausal women.
Campos SM
Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Rose C
Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
[TBL] [Abstract][Full Text] [Related]
20. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
